Hydrogel Embedded Dexamethasone for the Traumatic Brain Injury (TBI)

This Special Notice from the Walter Reed Army Institute of Research (WRAIR) seeks capability statements for providing Hydrogel Embedded Dexamethasone support for traumatic brain injury research. Respondents are requested to describe experience conducting studies to evaluate the pharmacokinetic profile and therapeutic efficacy of dexamethasone-embedded hydrogels in attenuating injury-induced edema, neuroinflammation, and behavioral dysfunction when administered post-injury.

The purpose of this Special Notice is to gather information to analyze small business capacity for a potential future set-aside to provide Hydrogel Embedded Dexamethasone for the Traumatic Brain Injury research program. Responses are due by June 3, 2020 and limited to five pages. Interested parties should demonstrate experience monitoring research animals, analyzing data, preparing reports and samples, and collaborating with WRAIR researchers on traumatic brain injury studies. Eligible respondents will assist in furthering the government's understanding of using dexamethasone-embedded hydrogels to treat traumatic brain injury.